Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer

Current Opinion in Chemical Biology

Volumn 23, Issue , 2014, Pages 39-46

  Rosalia, Rodney A ^a   Arenas Ramirez, Natalia ^a   Bouchaud, Grégory ^b   Raeber, Miro E ^a   Boyman, Onur ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b CEMAGREF   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED DNA; INTERLEUKIN 15; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IN VITRO STUDY; KIDNEY CARCINOMA; LEWIS CARCINOMA; LONG TERM SURVIVAL; LUNG EDEMA; MELANOMA B16; METASTASIS; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); ANIMAL; CHEMISTRY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; NEOPLASMS;

EID: 84907764279     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2014.09.006     Document Type: Review

References (49)

1. Boyman O., Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 2012, 12:180-190.
2. Malek T.R., Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 2010, 33:153-165.
3. Smith K.A. Interleukin-2: inception, impact, and implications. Science 1988, 240:1169-1176.
4. Taniguchi T., Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell 1993, 73:5-8.
5. Rosalia R.A., Silva A.L., Camps M., Allam A., Jiskoot W., van der Burg S.H., Ossendorp F., Oostendorp J. Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles. Cancer Immunol Immunother 2013, 62:1161-1173.
6. Boyman O., Kovar M., Rubinstein M.P., Surh C.D., Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006, 311:1924-1927.
7. Boyman O., Krieg C., Homann D., Sprent J. Homeostatic maintenance of T cells and natural killer cells. Cell Mol Life Sci 2012, 69:1597-1608.
8. Liao W., Lin J.X., Leonard W.J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013, 38:13-25.
9. Atkins M.B., Lotze M.T., Dutcher J.P., Fisher R.I., Weiss G., Margolin K., Abrams J., Sznol M., Parkinson D., Hawkins M., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999, 17:2105-2116.
10. Smith F.O., Downey S.G., Klapper J.A., Yang J.C., Sherry R.M., Royal R.E., Kammula U.S., Hughes M.S., Restifo N.P., Levy C.L., et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008, 14:5610-5618.
11. Klapper J.A., Downey S.G., Smith F.O., Yang J.C., Hughes M.S., Kammula U.S., Sherry R.M., Royal R.E., Steinberg S.M., Rosenberg S. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008, 113:293-301.
12. Boyman O., Surh C.D., Sprent J. Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin Biol Ther 2006, 6:1323-1331.
13. McDermott D.F., Atkins M.B. Application of IL-2 and other cytokines in renal cancer. Expert Opin Biol Ther 2004, 4:455-468.
14. Donohue J.H., Rosenberg S.A. The fate of interleukin-2 after in vivo administration. J Immunol 1983, 130:2203-2208.
15. Tomala J., Chmelova H., Mrkvan T., Rihova B., Kovar M. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy. J Immunol 2009, 183:4904-4912.
16. Klages K., Mayer C.T., Lahl K., Loddenkemper C., Teng M.W., Ngiow S.F., Smyth M.J., Hamann A., Huehn J., Sparwasser T. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res 2010, 70:7788-7799.
17. Antony P.A., Piccirillo C.A., Akpinarli A., Finkelstein S.E., Speiss P.J., Surman D.R., Palmer D.C., Chan C.C., Klebanoff C.A., Overwijk W.W., et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005, 174:2591-2601.
18. Krieg C., Letourneau S., Pantaleo G., Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A 2010, 107:11906-11911.
19. Levin A.M., Bates D.L., Ring A.M., Krieg C., Lin J.T., Su L., Moraga I., Raeber M.E., Bowman G.R., Novick P., et al. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 2012, 484:529-533.
20. Letourneau S., van Leeuwen E.M., Krieg C., Martin C., Pantaleo G., Sprent J., Surh C.D., Boyman O. IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc Natl Acad Sci U S A 2010, 107:2171-2176.
21. Tomala J., Kovarova J., Kabesova M., Votavova P., Chmelova H., Dvorakova B., Rihova B., Kovar M. Chimera of IL-2 linked to light chain of anti-IL-2 mAb mimics IL-2/anti-IL-2 mAb complexes both structurally and functionally. ACS Chem Biol 2013, 8:871-876.
22. Carmenate T., Pacios A., Enamorado M., Moreno E., Garcia-Martinez K., Fuente D., Leon K. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J Immunol 2013, 190:6230-6238.
23. Rao B.M., Driver I., Lauffenburger D.A., Wittrup K.D. High-affinity CD25-binding IL-2 mutants potently stimulate persistent T cell growth. Biochemistry 2005, 44:10696-10701.
24. Ahmadzadeh M., Rosenberg S.A. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006, 107:2409-2414.
25. Shanafelt A.B., Lin Y., Shanafelt M.C., Forte C.P., Dubois-Stringfellow N., Carter C., Gibbons J.A., Cheng S.L., Delaria K.A., Fleischer R., et al. A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nat Biotechnol 2000, 18:1197-1202.
26. Assier E., Jullien V., Lefort J., Moreau J.L., Di Santo J.P., Vargaftig B.B., Lapa e Silva J.R., Theze J. NK cells and polymorphonuclear neutrophils are both critical for IL-2-induced pulmonary vascular leak syndrome. J Immunol 2004, 172:7661-7668.
27. Margolin K., Atkins M.B., Dutcher J.P., Ernstoff M.S., Smith J.W., Clark J.I., Baar J., Sosman J., Weber J., Lathia C., et al. Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. Clin Cancer Res 2007, 13:3312-3319.
28. Muller D. Antibody-cytokine fusion proteins for cancer immunotherapy: an update on recent developments. BioDrugs 2014, 28:123-131.
29. Gillies S.D., Lan Y., Hettmann T., Brunkhorst B., Sun Y., Mueller S.O., Lo K.M. A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity. Clin Cancer Res 2011, 17:3673-3685.
30. Laurent J., Touvrey C., Gillessen S., Joffraud M., Vicari M., Bertrand C., Ongarello S., Liedert B., Gallerani E., Beck J., et al. T-cell activation by treatment of cancer patients with EMD 521873 (selectikine), an IL-2/anti-DNA fusion protein. J Transl Med 2013, 11:5.
31. Gillessen S., Gnad-Vogt U.S., Gallerani E., Beck J., Sessa C., Omlin A., Mattiacci M.R., Liedert B., Kramer D., Laurent J., et al. A phase I dose-escalation study of the immunocytokine EMD 521873 (selectikine) in patients with advanced solid tumours. Eur J Cancer 2013, 49:35-44.
32. Baluna R., Rizo J., Gordon B.E., Ghetie V., Vitetta E.S. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Natl Acad Sci U S A 1999, 96:3957-3962.
33. Klein C. Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer. J Immunother Cancer 2014, 2:I8.
34. Klein C., Waldhauer I., Nicolini V., Dunn C., Freimoser-Grundschober A., Herter S., Geven E., Boerman O., Nayak T., van Puijenbroek E., et al. Tumor-targeted, engineered IL-2 variant (IL-2v)-based immunocytokines for the immunotherapy of cancer. Cancer Res 2013, 73. abstract nr 486.
35. Becker J.C., Pancook J.D., Gillies S.D., Furukawa K., Reisfeld R.A. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 1996, 183:2361-2366.
36. Albertini M.R., Hank J.A., Gadbaw B., Kostlevy J., Haldeman J., Schalch H., Gan J., Kim K., Eickhoff J., Gillies S.D., et al. Phase II trial of hu14.18-IL2 for patients with metastatic melanoma. Cancer Immunol Immunother 2012, 61:2261-2271.
37. Yang R.K., Kalogriopoulos N.A., Rakhmilevich A.L., Ranheim E.A., Seo S., Kim K., Alderson K.L., Gan J., Reisfeld R.A., Gillies S.D., et al. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival. Cancer Immunol Immunother 2013, 62:1303-1313.
38. Weide B., Eigentler T.K., Pflugfelder A., Zelba H., Martens A., Pawelec G., Giovannoni L., Ruffini P.A., Elia G., Neri D., et al. Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses. Cancer Immunol Res 2014, 2:668-678.
39. Gutbrodt K.L., Schliemann C., Giovannoni L., Frey K., Pabst T., Klapper W., Berdel W.E., Neri D. Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Sci Transl Med 2013, 5:201ra118.
40. Dubois S., Mariner J., Waldmann T.A., Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 2002, 17:537-547.
41. Bessard A., Sole V., Bouchaud G., Quemener A., Jacques Y. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther 2009, 8:2736-2745.
42. Dubois S., Patel H.J., Zhang M., Waldmann T.A., Muller J.R. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J Immunol 2008, 180:2099-2106.
43. Epardaud M., Elpek K.G., Rubinstein M.P., Yonekura A.R., Bellemare-Pelletier A., Bronson R., Hamerman J.A., Goldrath A.W., Turley S.J. Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res 2008, 68:2972-2983.
44. Haffner A.C., Garbe C., Burg G., Buttner P., Orfanos C.E., Rassner G. The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients. Br J Cancer 1992, 66:856-861.
45. Yang J.C., Sherry R.M., Steinberg S.M., Topalian S.L., Schwartzentruber D.J., Hwu P., Seipp C.A., Rogers-Freezer L., Morton K.E., White D.E., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003, 21:3127-3132.
46. Shusterman S., London W.B., Gillies S.D., Hank J.A., Voss S.D., Seeger R.C., Reynolds C.P., Kimball J., Albertini M.R., Wagner B., et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol 2010, 28:4969-4975.
47. Johannsen M., Spitaleri G., Curigliano G., Roigas J., Weikert S., Kempkensteffen C., Roemer A., Kloeters C., Rogalla P., Pecher G., et al. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer 2010, 46:2926-2935.
48. Carnemolla B., Borsi L., Balza E., Castellani P., Meazza R., Berndt A., Ferrini S., Kosmehl H., Neri D., Zardi L. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 2002, 99:1659-1665.
49. Navid F., Sondel P.M., Barfield R., Shulkin B.L., Kaufman R.A., Allay J.A., Gan J., Hutson P., Seo S., Kim K., et al. Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol 2014, 32:1445-1452.